🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

23 recruiting trials

for Generalized Myasthenia Gravis (gMG)

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) NCT06987539Phase 214 sites📍 Chicago📍 Philadelphia📍 Austin Amgen · Tests: Inebilizumab Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) NCT04202341n/a51 sites📍 Birmingham📍 Scottsdale📍 Fresno Alexion Pharmaceuticals, Inc. GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) NCT07058298EARLY Phase 11 site📍 Wuhan Daishi Tian · Tests: GC012F injection Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) NCT07596784Phase 310 sites📍 Beijing📍 Changchun📍 Fuzhou Alexion Pharmaceuticals, Inc. · Tests: Ravulizumab ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis NCT07673627Phase 28 sites📍 Carlsbad📍 Miami📍 Las Vegas argenx · Tests: Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis NCT07246564Phase 412 sites📍 Beijing📍 Changchun📍 Changsha UCB Biopharma SRL · Tests: Rozanolixizumab Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis NCT07411963n/a8 sites📍 Nice📍 Bron📍 Garches Centre Hospitalier Universitaire de Nice · Tests: early use of Ravulizumab A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis NCT06055959Phase 2, Phase 39 sites📍 Chicago📍 Denton📍 Milan UCB Biopharma SRL · Tests: Zilucoplan Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis NCT06909253n/a11 sites📍 Bydgoszcz📍 Gdansk📍 Katowice AstraZeneca · Tests: Ravulizumab Zilucoplan for Severe gMG Exacerbations NCT07215949Phase 33 sites📍 Tampa📍 Kansas City📍 Columbus Miriam Freimer · Tests: Zilucoplan® PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis NCT06607627Phase 313 sites📍 Washington D.C.📍 Norfolk📍 Joinville Alexion Pharmaceuticals, Inc. · Tests: Gefurulimab Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) NCT07215650Phase 110 sites📍 Fuzhou📍 Guangzhou📍 Guangzhou Candid Therapeutics · Tests: Cizutamig RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis NCT06359041Phase 1, Phase 217 sites📍 Orange📍 Sacramento📍 San Francisco Cabaletta Bio · Tests: CABA-201, CABA-201 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) NCT06463587Phase 3154 sites📍 Phoenix📍 Longmont📍 Farmington Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of … · Tests: Placebo, Cladribine Low Dose, Cladribine High Dose ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis NCT07294170n/a37 sites📍 Carlsbad📍 Miami📍 Miami argenx · Tests: Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) NCT06909214Phase 418 sites📍 La Jolla📍 Rancho Mirage📍 Boca Raton argenx · Tests: Efgartigimod PH20 SC A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab NCT07221838Phase 412 sites📍 Chicago📍 Schaumburg📍 Neptune City Alexion Pharmaceuticals, Inc. · Tests: Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone Study of Ultomiris® (Ravulizumab) Safety in Pregnancy NCT06312644n/a7 sites📍 Boston📍 Melbourne📍 Paris Alexion Pharmaceuticals, Inc. · Tests: Ultomiris Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases NCT06626919Phase 114 sites📍 Los Angeles📍 Orange📍 Palo Alto Kite, A Gilead Company · Tests: anito-cel, Cyclophosphamide, Fludarabine A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy NCT07595653n/a30 sites📍 Acquaviva delle Fonti📍 Ancona📍 Bari argenx Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis NCT06967480n/a23 sites📍 Bergamo📍 Bologna📍 Bologna Alexion Pharmaceuticals, Inc. · Tests: Ravulizumab Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia NCT07247279n/a7 sites📍 Kazan'📍 Moscow📍 Novosibirsk AstraZeneca ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod NCT07284420Phase 233 sites📍 Carlsbad📍 Miami📍 Tampa argenx · Tests: Efgartigimod IV, Empasiprubart IV
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy